Incyte Reports Encouraging 24-Week Results From Phase 3 STOP-HS Program Of Povorcitinib

Incyte Corporation (INCY) announced encouraging 24-week data from its pivotal Phase 3 STOP-HS program for povorcitinib in hidradenitis suppurativa, demonstrating nearly 60% of efficacy-evaluable patients achieved HiSCR50, alongside significant improvements in skin pain for 62%-70% of patients. These positive results, following previously met primary endpoints, will support planned regulatory submissions for povorcitinib in Europe in 2025 and the U.S. in early 2026, positioning the drug as a strong candidate for this chronic inflammatory skin condition.

Analysis

Incyte Corporation (INCY) has significantly strengthened the clinical case for its investigational drug, povorcitinib, with the release of positive 24-week data from its pivotal Phase 3 STOP-HS program for hidradenitis suppurativa (HS). Building upon the previously successful 12-week primary endpoints, the new results demonstrate durable and high-level efficacy. Nearly 60% of efficacy-evaluable patients on povorcitinib achieved HiSCR50, a 50% reduction in abscess and inflammatory nodule counts. The drug's potent effect is further underscored by the substantial proportion of patients achieving higher response thresholds, with 31%-40.3% reaching HiSCR75 and 9.2%-21.3% achieving complete clearance (HiSCR100). Critically for this chronic and painful condition, the treatment also delivered meaningful quality-of-life improvements, with 62%-70% of patients reporting mild or no skin pain by Week 24. This comprehensive data package substantially de-risks the asset and provides a firm basis for the planned regulatory submissions in Europe in 2025 and the U.S. in early 2026, establishing a clear timeline toward potential commercialization.

Key Decisions for Investors

• The robust 24-week Phase 3 data significantly de-risks povorcitinib and supports a positive outlook on this key pipeline asset, warranting a re-evaluation of Incyte's long-term growth trajectory.
• Investors should focus on the defined regulatory timeline, with filings in Europe (2025) and the U.S. (early 2026) serving as the next major catalysts for potential value realization.
• Given the high efficacy rates and strong pain reduction data, it is prudent to model for a strong competitive profile and significant commercial potential for povorcitinib in the hidradenitis suppurativa market, pending regulatory approval.